68Ga-PSMA-11 PET/CT in primary and recurrent prostate carcinoma

• Verfasst von: Körber, Stefan A. [VerfasserIn]
• Verfasst von: Will, Leon [VerfasserIn]
• Verfasst von: Kratochwil, Clemens [VerfasserIn]
• Verfasst von: Häfner, Matthias [VerfasserIn]
• Verfasst von: Rathke, Hendrik [VerfasserIn]
• Verfasst von: Kremer, Christophe [VerfasserIn]
• Verfasst von: Merkle, Jonas [VerfasserIn]
• Verfasst von: Herfarth, Klaus [VerfasserIn]
• Verfasst von: Haberkorn, Uwe [VerfasserIn]
• Verfasst von: Debus, Jürgen [VerfasserIn]
• Verfasst von: Giesel, Frederik L. [VerfasserIn]
• Titel: 68Ga-PSMA-11 PET/CT in primary and recurrent prostate carcinoma
• Titelzusatz: implications for radiotherapeutic management in 121 patients
• Verf.angabe: Stefan A. Koerber, Leon Will, Clemens Kratochwil, Matthias F. Haefner, Henrik Rathke, Christophe Kremer, Jonas Merkle, Klaus Herfarth, Klaus Kopka, Peter L. Choyke, Tim Holland-Letz, Uwe Haberkorn, Juergen Debus, Frederik L. Giesel
• Jahr: 2019
• Umfang: 7 S.
• Fussnoten: Published on July 5, 2018 ; Im Titel ist "68" in 68Ga-PSMA-11 PET/CT hochgestellt ; Gesehen am 12.03.2019
• Titel Quelle: Enthalten in: Journal of nuclear medicine
• Ort Quelle: New York, NY : Soc., 1964
• Jahr Quelle: 2018
• Band/Heft Quelle: 60(2018), 2, Seite 234-240
• ISSN Quelle: 2159-662X
• ISSN Quelle: 1535-5667
• DOI: doi:10.2967/jnumed.118.211086
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Oncology: GU
• Sach-SW: PET/CT
• Sach-SW: prostate cancer
• Sach-SW: PSMA
• Sach-SW: Radiation Therapy Planning
• Sach-SW: radiotherapy
• Sach-SW: staging
• K10plus-PPN: 1590142985

Abstract

The present study analyzed the impact of Gallium-68 (68Ga)-labeled prostate-specific membrane antigen-HBED-CC (68Ga-PSMA-11) positron-emission tomography (PET)/computed tomography (CT) on radiotherapeutic management in a large cohort of men with primary or recurrent disease. Methods: This study investigated 121 men with carcinoma of the prostate who underwent 68Ga-PSMA-11 PET/CT as well as conventional imaging. 50 patients were treatment naive, 11 had persistent prostate-specific antigen (PSA) soon after surgery and 60 presented with recurrent PSA following definitive therapy. Changes in TNM classification of malignant tumors (TNM) stage and radiotherapeutic management after 68Ga-PSMA-11 imaging were compared to results achieved with conventional imaging. Results: In total, a change in TNM stage and radiotherapeutic management was observed for 49 patients (40.5%) and 62 patients (51.2%), respectively. In treatment naïve patients, a change in TNM stage and radiotheraeutic plan occurred in 26.0% and 44.0% of the cohort respectively. For patients with PSA persistence or recurrence, TNM and radiotherapeutic management changed in 50.7% and 56.3% respectively. Conclusion: 68Ga-PSMA-11 PET/CT may shortly become an indispensable tool for detecting prostate cancer lesions in treatment-naïve patients as well as in men with recurrent disease or persistent PSA and seems to be very helpful in personalizing radiotherapeutic management to the individual patients’ distribution of disease.